Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

• Published in: Cancer chemotherapy and pharmacology Vol. 85; no. 6; pp. 1109 - 1117
• Main Authors: Ogasawara, Ken, Smith, William B., Xu, Christine, Yin, Jian, Palmisano, Maria, Krishna, Gopal
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2020; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Area Under Curve; Cancer Research; Case-Control Studies; Dosage; End-stage renal disease; Enzyme inhibitors; Female; Follow-Up Studies; Humans; Janus kinase; Janus kinase 2; Janus Kinase 2 - antagonists & inhibitors; Kidney diseases; Kidney Failure, Chronic - drug therapy; Kidney Failure, Chronic - enzymology; Kidney Failure, Chronic - pathology; Liver diseases; Liver Diseases - drug therapy; Liver Diseases - enzymology; Liver Diseases - pathology; Male; Maximum Tolerated Dose; Medicine; Medicine & Public Health; Middle Aged; Myelofibrosis; Oncology; Original Article; Pharmacokinetics; Pharmacology/Toxicology; Prognosis; Pyrrolidines - administration & dosage; Pyrrolidines - pharmacokinetics; Studies; Sulfonamides - administration & dosage; Sulfonamides - pharmacokinetics; Survival Rate; Tissue Distribution; Young Adult; Tolerability; Hepatic impairment; Renal impairment; Fedratinib; Pharmacokinetics
• ISSN: 0344-5704; 1432-0843; 1432-0843
• DOI: 10.1007/s00280-020-04084-2

Purpose Fedratinib is an oral, selective Janus kinase 2 inhibitor that is approved in the United States for the treatment of patients with intermediate-2 or high-risk myelofibrosis. Pharmacokinetics and tolerability of fedratinib in subjects with renal impairment (RI) and hepatic impairment (HI) wer...